日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

High-end talent seeks success in China's fast-growing pharmaceutical sector

By LIU ZHIHUA | China Daily | Updated: 2021-08-10 09:54
Share
Share - WeChat
Workers of Anhui Zhifei Longcom Biopharmaceutical Co Ltd check packaged drugs at the company's plant in Hefei, Anhui province, in May. [Photo/Xinhua]

Chinese biotech companies are becoming increasingly attractive to high-end talent, thanks to the rapid growth of China's healthcare enterprises, according to industry insiders.

Joshua Liang, CEO of Clover Pharmaceuticals, said Chinese local pharmaceutical and biotech companies are attracting not only China-born talent, but also more foreign expertise and returning Chinese.

"The COVID-19 pandemic has made it hard for people overseas to come to China because of quarantine and the travel restrictions, but the trend will resume over the next year or two," Liang said.

"I think this really speaks to the growing innovation of Chinese pharmaceutical and biotech companies, and is a really exciting trend," he said.

Clover has been able to attract top talent from around the world to join its COVID-19 vaccine development program, and currently has employees in the United States, Europe, Southeast Asia and Latin America.

In 2016, Clover had no more than 15 people, who were all lab-based scientists. Now it has over 550 staff in over 15 countries, with a rich pipeline that includes a phase-3 COVID-19 vaccine candidate.

Hays plc, a leading global professional recruiting group, said in a recent report that the rapid development of China's healthcare companies has increased demand for professionals with international experience in the areas including marketing, research and development, digitalization and more.

Although the national healthcare industry has been impacted due to the pandemic, it has been given new development opportunities driven by preferential domestic policy trends and the driving force of the capital market, it said.

"China is the first major economy to recover from the pandemic. The Chinese market has also provided a broad development space for the healthcare industry, where the proportion of local companies is more than ever before. This means rich and diverse job opportunities for candidates," says Simon Lance, managing director of Hays Greater China.

"For Hays, especially in healthcare, domestic clients are a markedly increasing proportion of our overall business. We believe that the growth of local companies will create more opportunities for talent and further drive the healthy flow of expertise to stimulate the innovation potential of Chinese companies," Lance said.

With an attractive salary package and management authority, executives of multinational companies are more willing to join local enterprises to expand their career horizons, while candidates for midlevel positions prefer the mature training systems of multinational companies instead, Hays said.

Local enterprises are normally able to offer attractive remuneration and even equity incentives to talent, it said.

Hays also found that local innovative pharmaceutical companies are paying more attention to their business development divisions and treating them as one of their most crucial core competencies.

The main function of a BD division is "license in and license out"-that means helping the company introduce new patents to save time on R&D, and to sell their pipelines to earn revenue.

Hays said that the BD position requires a candidate to possess a multifaceted skill set. An appropriate candidate must have both pharmaceutical knowledge and good business awareness. Therefore, candidates with doctorate degrees in pharmacy-related majors and business backgrounds are prioritized by employers.

Wei Dong, CEO of EdiGene, a Beijing-based private biotech company developing genome editing technologies, said talent-both locally grown, returnees from overseas-has contributed to the growing pharmaceutical industry's innovation capabilities.

Translating scientific findings into innovative therapies requires a comprehensive understanding of drug development processes, including research, preclinical studies, drug product manufacturing, regulations and clinical trial designs, which take many years of experience, Wei said.

It is natural that scientists and business leaders with experience in multinational companies have become instrumental in founding and growing China's pharmaceutical and biotech startups. But such a trend will shift in the future as new scientific and business leaders emerge from the current boom in innovative biotech companies in China, he said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久婷婷色一区二区三区 | 韩国在线精品福利视频在线观看 | 久久在线中文字幕 | 亚洲精品国产偷自在线观看 | 久久综合日韩亚洲精品色 | 一区二区国产精品 | 天天操天天拍 | 国产一区在线免费 | 四虎网站在线观看 | 一级大片久久 | 欧美黑人性暴力猛交免费看 | 国产一区二区久久精品 | 亚洲人人 | 亚洲免费久久 | 欧美一级毛片欧美大尺度一级毛片 | 亚洲综合精品一区二区三区中文 | 色综合久久综精品 | 精品免费久久久久久成人影院 | 欧美精品中文字幕久久二区 | 日韩成人 | 亚洲成人综合视频 | 亚洲日本一区二区三区 | 久久久久毛片成人精品 | 在线精品亚洲欧美日韩国产 | 国产高清在线精品一区免费97 | 精品伊人久久久 | 色婷婷综合在线 | 国产精品69人妻无码久久久 | 国产成人综合久久 | 一级一级 a爱片免费视频 | 国产目拍亚洲精品99久久精品 | xvideos korean | 99在线播放视频 | 欧美视频第一页 | 久久久久一区二区三区 | 啊啊啊好紧好爽 | 亚洲最大视频网站 | 日韩免费在线视频 | 欧美一级二级在线观看 | 欧美日韩国产在线人成dvd | 免费一级片观看 |